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Abstract LDL receptor elated protein (LRP) is a ubiquitously 
expressed cell surface receptor that binds, at least in vitro, a 
plethora of ligands among them c~2-macroglobulin and lactoferrin 
(Lf). The function of LRP in internalisation and distribution of 
ligands within cellular metabolism is still unclear. We here inves- 
tigated by combined ligand- and immunoblotting the participation 
of LRP/a2MR and its associated protein (RAP) in receptor me- 
diated endocytosis of Lf into rat liver. We found LRP highly 
enriched in sucrose density gradient fractions around density I. I0 
g/ml, previously characterised as endosomal fractions. RAP was 
concentrated in distinct fractions around density 1.14 g/ml. This 
separation of RAP from LRPIa2MR is physiologically meaning- 
ful as RAP avidly binds to LRPIa2MR and by that shuts off aH 
ligand binding function. In endosomal fractions we found one 
single binding protein for ~2Sl-labelled Lf. With a specific anti 
LRPla2MR antibody and ligand blotting with 125I-labelled RAP 
this endosomal Lf binding site was verified to be LRP/azMR. 
Endosomes did not bind labelled Lf when prepared from rats that 
received an intravenous injection of Lf (20 mg per animal) 20 rain 
prior to preparation. Surprisingly we immunodetected Lf in these 
endosomes at a position around 600 kDa, comigrating with LRP/ 
c~2MR. We determined Lf binding to be optimal at pH 5.8, what 
led us to suggest he existence of a very stable LF-LRP/c~2MR 
complex in endosomes. These data support the idea of effective 
binding of Lf at pH as found in inflamed tissue environment where 
Lf is reported to be involved in leukocyte mediated inflammation 
regulation. 
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I. Introduction 
Numerous tudies uggest that the liver can play a role in the 
clearance of lactoferrin (Lf) from the circulation. In contrast 
to milk derived Lf, which is produced by synthesis in the lactat- 
ing breast glands, blood born Lf is produced in leukocytes and 
set free into the blood after stimulation of leukocytes to release 
the content of their granules. Whether uptake into liver is me- 
diated in part by a sui generis receptor emains a matter of 
dispute. It has been reported that binding of Lf to cells is 
mediated via several mechanisms, but internalisation is likely 
to be mediated by a receptor mediated process [1-5]. A candi- 
date receptor for this might be LRP/a2MR. The current opin- 
ion on the performance of the multifunctional LRP/a2MR was 
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outlined lately in several reviews [6-8]. It is believed that the 
clustering of cysteine-rich type A binding repeats, resembling 
those found in LDL receptor, is the molecular principle for the 
ability to bind a variety of ligands so far thought o be unre- 
lated. The physiological importance of recognition of the 
hitherto identified or proposed ligands - activated c~2-macro- 
globulin (~2M*), apolipoprotein E (apoE), lipoprotein lipase 
(LPL), plasminogen activators and complexes with their inhib- 
itor (PA and PA/PAI-1), lipoprotein(a), pseudomonas exotoxin 
A, human rhinovirus, Lf and the so-called receptor associated 
protein (RAP) - by a single receptor entity is one crucial ques- 
tion to be answered [9-27]. Within the description of miscella- 
neous ligands of LRP/~2MR also in vitro binding of Lf was 
demonstrated [1]. Together with our first description of the 
potency of Lf to inhibit chylomicron remnant uptake in vivo 
[4] these data prompted us to more directly investigate a possi- 
ble physiologic importance of the binding of Lf to LRP/c~2MR. 
In a first step we here confirm the identity of LRP/a2MR with 
the sole Lf-binding protein found in endosomes by ligand- and 
immunoblotting. Direct evidence for the participation of LRP/ 
~2MR will emerge from the evidence of Lf-LRP/~2MR com- 
plexes in liver endosomes and emphasise that plasma Lf is 
cleared by receptor mediated internalisation. We will demon- 
strate that binding is optimal at pH 5.8 which explains the 
finding of intact receptor ligand complexes in the acidic en- 
dosomal compartment and supports the idea of highly effective 
binding at pH as found in inflamed tissue environment. Numer- 
ous reports exist about Lf's action after its release from acti- 
vated leukocytes in inflamed tissues ([28] and references 
therein). This process also elevates blood levels of Lf consider- 
ably that led us to suggest a role of the Lf-LRP/~2MR system 
in inflammation. 
2. Experimental procedures 
2.1. Materials 
We obtained chemicals from Sigma and Na(~ZsI) for protein iodina- 
tion from NEN. Suramin was kindly provided by Bayer (Leverkusen, 
Germany). Human ~2M was from Boehringer (Mannheim, Germany) 
and was activated (~zM*) with methylamine according to Barret [29]. 
Polyclonal rabbit anti LRP/~2MR antibody, recognising the 515 kDa 
ligand binding and 85 kDa transmembrane portion of LRP/~2MR as 
well as the 39 kDa RAP, was kindly provided by J. Gliemann (Univer- 
sity Aarhus, Denmark). Recombinant glutathione S-transferase (GST) 
and rat 39-kDa fusion protein (designated GST-RAP) were produced 
in DH5~ bacteria transformed with a GST-RAP expression plasmid 
(kindly provided by J. Herz, UTHSC at Dallas) according to Herz. et 
al. [21]. Full binding activity of the isolated product was achieved after 
extensive dialysis in chaotropic buffers (1 x 1000 ml 5 M urea, 18 h, 
10 × 20 ml from 4 M to 0.I M urea 1 h, 1 × 1000 ml TBS, 18 h, 4°C). 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00082-8 
M. Meih'nger et aL /FEBS Letters 360 (1995) 70-74 71 
Ligands were radiolabelled using IODO-BEADS (Pierce, Rockford, 
IL) according to the manufacturer's instructions. Typically 100 pg of 
protein in 100/11 TBS (Tris-buffered saline, 50 mM Tris, 150 mM NaC1, 
pH 7.4) were labelled with 100/.tCi of Na(125I) using 1 bead to a specific 
activity of 34  x l0  6 cpm//~g and extensively dialysed against TBS/0.1 
mM EDTA. 
2.2. Animals and tissue fractionation 
Male Sprague-Dawley rats (weight approx. 200 g) were received 
from Institut ffir Versuchstierkunde, University of Vienna. Endosomes 
were isolated from rat liver homogenates sentially as described [30]. 
Ligands (Lf: 7 mg per animal, c~2M*: 2 mg per animal) were injected 
as described [4] and were circulating in anaesthetised animals for 20 
min. 
2.3. Electrophoresis and blotting 
Typically 80 pg of protein (non-reduced and non-boiled) per lane 
were loaded onto 7.5% linear or 4-15% SDS-PAGs as indicated. After 
electrophoresis the samples were transferred to nitrocellulose mem- 
branes at 12°C. Individual strips were incubated in 1 ml of incubation 
buffer (Tris-buffered saline (TBS) 50 mM Tris, 150 mM NaCl, pH 7.4, 
2 mM CaC12, 0.01% Triton X-100, Pierce Rockford, IL) after blocking 
with 5 mg non-fat dry milk per ml (2 h each). Immunodetection was 
done essentially as described [31] using HRP-conjugated second anti- 
bodies (Bio-Rad, Vienna) and the ECL reagent (Amersham, Vienna) 
according to the specifications of the manufacturer for visualisation. 
For quantification ofbound radioactive ligands densitometric s anning 
of autoradiographs was performed with a scanner system (IMAGE- 
MASTER, Pharmacia, Sweden). 
3. Results 
3.1. LRP/~2MR but not its associated protein (RAP) is 
enriched in endosomes 
A light particle fraction obtained from differential centrifu- 
gation was subjected to zonal sucrose density gradient centrifu- 
gation. Fractions in the range of 1.06 to 1.15 g/ml, as character- 
ised by marker protein enrichment in a previous paper [30], 
were separated by electrophoresis and blotted onto nitrocellu- 
lose membranes. By immunodetection we observed the highest 
enrichment of LRP/~zMR in endosomal fractions with a den- 
sity of  1.10 g/ml (Fig. 1). Interestingly, we could not detect RAP 
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Fig. 1. Immunodetection f LRP and RAP in sucrose density gradient 
fractions. Endosomal fractions were prepared from the livers by differ- 
ential and sucrose gradient centrifugation. The fractions from density 
1.06 (left lane) to 1.16 g/ml (rightmost lane) were separated by 4-15% 
gradient SDS-PAGE and blotted onto nitrocellulose membranes (*de- 
notes peak endosomal fraction with density 1.10 g/ml). Arrows give the 
approximate positions of 600 kDa (LRP/a2MR and the tetramer form 
of ~2M), 85 kDa (transmembrane part of LRP/c~2MR ) and 40 kDa 
(receptor associated protein RAP) 
,*--  515  kDa 
85  kDa 
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Fig. 2. Identification of Lf-BP by ligand- and immunoblotting. Rat 
liver endosomal fractions (80 ,ug protein per lane of the 1.10 g/ml peak 
endosomal fraction as described in Fig. 1) were separated by 7.5% 
SDS-PAGE, blotted onto nitrocellulose membranes and stained with 
Ponceau red (strip 1). Replicate strips were subjected to ligand- and 
immunoblot analysis. Strips show the results of ligand blotting with 
~25I-labelled Lf (strip 2 and 3, 0.9 x 106 cpm/ml) and ~2SI-labelled GST- 
RAP (strip 5 and 6, each 0.7 x 106 cpm/ml) in the absence and presence 
(strip 3 and 6) of 5 mg Suramin per ml. Strip 4 shows the result of 
immunoblot analysis with a polyclonal rabbit antibody, raised against 
purified LRP/~2MR, as first antibody, followed by HRP labelled sec- 
ond antibody and subsequent visualisation by ECL. One typical set of 
results out of three identical experiments i  shown. 
in these fractions, although the primary antibody is able to 
recognise RAP with high sensitivity. We localised the so-called 
receptor associated protein RAP clearly separated from the 
receptor in gradient fractions around 1.13 g/ml which contain 
Golgi-derived material as we described earlier [30]. Also lyso- 
somal ocalisation can be excluded, as fractions > 1.19 g/ml were 
virtually free of RAP. 
3.2. Identity of  Lf-binding protein (Lf-BP) with LRP/ot2MR in 
endosomes 
Numerous types of binding sites for Lf  have been postulated 
on the cell surface. Their involvement in endocytosis has not 
been investigated in detail. We therefore tested by ligand blot- 
ting with radiolabelled Lf  how many binding sites are internal- 
ised and thus can be found in purified endosomes. In Fig. 2 a 
Ponceau-stained sample of an endosomal fraction (strip 1) is 
shown which was subjected to ligand blotting (strip 2) with 
[125I]Lf resulting in a single prominent band migrating at ap- 
prox. 600 kDa. This signal comigrates with the one resulting 
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Fig. 3. Immunodetection f internalised ligands and determination f binding function in endosomes. Rats were injected with unlabelled Lf (Fig. 
3A and B, Lf-Endosomes) and ~2M (Fig. 3C and D, azM-Endosomes) and subcellular fractions prepared as described. The unlabelled ligands 
recovered in these fractions (free Lf at 70 kDa and a2M at 720 kDa and fragments, marked by white star) were analysed as described in Fig. 2 by 
incubation with specific rabbit primary antibodies followed by HRP-labelled anti-rabbit IgG and visualised by ECL (2 min exposure). This membranes 
were subjected to a second overlay (B and D) with radiolabelled Lf to determine unsaturated binding capacity after autoradiographic visualisation 
(16 h exposure) of bound radioactivity. Arrows give the approximate positions of 600 kDa (LRP/a2MR and a2M), 85 kDa (transmembrane part 
of LRP/a2MR), 70 kDa (free Lf). One representative s t of results from two identical experiments is shown. 
from developing this preparation with a polyclonal antibody 
raised against purified azMR (strip 4). The exact comigration 
was also verified by alignment of lanes split into two halves and 
developed by ligand- and immunodetection respectively (not 
shown). The migration behaviour of the Lf-BP was also indis- 
tinguishable from the RAP-BP described to be the LRP/a2MR. 
Ligand blotting with [~25I]GST-RAP again showed an identi- 
cally migrating reaction product at approx. 600 kDa (strip 5). 
Finally, the binding of Lf as well as of GST-RAP to LRP/a2MR 
was abolished by 5 mg Suramin per ml (strips 3 and 6), which 
prevents internalisation of Lf and chylomicron remnants in 
tissue culture, as demonstrated arlier [4]. We thus demonstrate 
the existence of one sole protein capable of binding Lf and RAP 
in endosomes, which is, with high likelihood, LRP/a2MR. 
3.3. L f  injected into animals & recovered in the endocytotic 
compartment of the liver complexed to LRPla2MR 
We have previously shown that coinjection of excess Lf with 
labelled chylomicron remnants led to exclusion of remnants 
from the endocytotic compartment. Labelled Lf was accumu- 
lated by hepatocytes into vesicles of a density around 1.10 g/ml 
most likely endosomes [4]. To bring further insight whether 
LRP/a2MR is involved in the transport of Lf from plasma into 
cells, we injected unlabelled Lf into rats 20 min prior to removal 
of livers and subsequent subcellular fractionation. Fractions 
from density 1.06 to 1.18 g/ml were separated by SDS-PAGE 
and transferred to nitrocellulose and Lf immunodetected using 
a polyclonal antibody. Unexpectedly, immunopositive material 
at approx. 70 kDa (flee Lf, arrow Fig. 3A) was not enriched 
in the peak endosomal fraction (lane marked with asterisk). In 
this fraction, however, a strong signal at 600 kDa was detected. 
At that position a complex of Lf bound to LRP/a2MR would 
be found. This slow migrating form of Lf was detected exclu- 
sively in endosomal fractions of rats injected with Lf but did 
not occur in the plasma. If this was indeed Lf tightly bound to 
the receptor we reasoned that in this fractions the binding of 
Lf should be diminished ue to saturation of the receptors. We 
therefore subjected the same nitrocellulose membrane to a sec- 
ond overlay with 125I-labelled Lf (Fig. 3B) and could not detect 
any binding. As a control we prepared matching fractions from 
rats preinjected with a2M* (Fig. 3C and D). Activated a2M was 
substantially enriched in the fraction of a density of 1. l0 g/ml. 
Under these conditions the 720 kDa protein a2M was frag- 
mented to typical subunit fragments, mainly 360 and 80 kDa 
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Fig. 4. Influence of pH on the binding of Lf to LRP/e2MR. Endosomal 
fractions were prepared as described in Fig. 2 and were subjected to 
ligand blotting. Strips were individually incubated with 1-2 x l0  6 cpm 
of labelled Lf per ml as described in section 2, in appropriate buffers 
from pH 4.0 to 7.4. Washes were performed at the pH of incubation. 
Autoradiographs of strips were quantitated bydensitometric s anning. 
The maximal value obtained was set to 100% (symbols denote values 
obtained from three independent experiments). 
(white asterisks Fig. 3C) as described by Barret et al. [29]. We 
subjected the nitrocellulose membrane to a second overlay with 
~2SI-labelled Lf (Fig. 3D) and clearly detect binding. Thus, LRP/ 
c~2MR present in Lf-loaded endosomal preparations was satu- 
rated with Lf. On the other hand, in fractions prepared from 
a2M*-endosomes, the huge amount of ~2M*, as immunode- 
tected, did not block access of [~25I]Lf to the receptor and 
binding of [125I]Lf was clearly visible on the autoradiograph. 
3.4. Binding of L f  to LRP/%MR is maximal at pH 5.8 
Dissociation of ligands from receptors in endosomes i  medi- 
ated by pH induced conformation changes. To characterise the 
interaction of Lf with the receptor in endosomes we studied its 
pH dependency. For e2M*, the maximal binding was reported 
at pH 7.8 [35]. The affinity of [~25I]Lf to LRP/c~2MR was deter- 
mined by incubating nitrocellulose strips at pH ranging from 
3.5 to 7.4 for one hour, followed by extensive washing at the 
same pH. Autoradiographs were scanned densitometrically. 
The results are shown in Fig. 4 as the percentage of maximal 
binding detected at pH 5.8 calculated from three independent 
experiments. We consistently found a maximal binding around 
pH 5.8 whereas around pH 7.4 and 4.0 binding was reduced. 
4. Discussion 
LRP is an ubiquitously expressed cell surface receptor that 
binds, at least in vitro, a plethora of ligands. The function of 
LRP/~2MR in internalisation a d distribution of these ligands 
is still unclear. It was demonstrated byHerz et al. [32] by tracing 
with antibodies that this receptor can carry out receptor medi- 
ated endocytosis. The so called receptor associated protein 
(RAP) copurified with the receptor upon affinity purification 
with LRP/~2MR and inhibited most, if not all, ligand binding 
and was hypothesised to be a regulatory unit for the receptor. 
We here present data that confirm the localisation of LRP/ 
~2MR in endosomes but show that RAP is enriched in a com- 
partment of distinct density. This suggests that, as the fractions 
were prepared from intact organelles, RAP is normally sepa- 
rated from LRP/ct2MR. RAP has been recently found to inhibit 
chylomicron uptake in animals where overexpression induced 
a high plasma level of the normally intracellular protein [33]. 
Our findings give a first hint for the compartment where RAP 
is separated when it is not needed to shut off receptor function. 
RAP was also discussed as the immunogenic stimulus causing 
Heyman nephritis. Under what metabolic ircumstances, if 
any, RAP is presented to antibody producing cells in complex 
with gp330, another member of the LDL receptor family, re- 
mains to be elucidated [34]. 
In our first report about competition of chylomicron 
remnants with Lf for uptake into hepatocytes in vivo, this was 
considered to arise from an indiscriminate random sequence 
homology. The subsequent discovery of various proteins bind- 
ing to LRP/(z2MR led us to investigate more intensively a phys- 
iologic significance of the affinity of Lf to LRP/~2MR. We here 
present experiments hat strongly advocate for a factual igand 
role of Lf to LRP/~zMR. Our experiments demonstrate the 
clearance of Lf from the bloodstream into liver endosomes by 
a solitary receptor. We found after intravenous injection of Lf 
a high molecular weight form of LF at about 600 kDa, presum- 
ably a Lf/Lf-receptor complex in liver endosomes. This com- 
plex, accordingly, immunostained with antibodies against LRP/ 
~z2MR. Such in vivo Lf-loaded endosomes were evidently satu- 
rated as we saw no further capacity to bind Lf in ligand blots. 
In control experiments, endosomes prepared after injection of 
~2M under otherwise identical conditions bound labelled Lf. 
Evidently ~2 M was at least partially dissociated from LRP/ 
e2MR in endosomes as we found fragments of the molecule at 
lower molecular weights as described [29]. This finding parallels 
our previous results that showed independent binding of Lf and 
%M* to LRP/~2MR. 
Usually the low pH in endosomes induces a conformation 
shift that brings forward the release of ligands from the recep- 
tor. An explanation why this was not operative for the Lf-LRP/ 
~2MR complex came from our experiment showing optimal 
binding of Lf at pH 5.8. We cannot at this moment clearly 
deduce from the experiments hat Lf is functioning as a non 
dissociable ligand in vivo. If so, this would anticipate that the 
receptor is not resorted to the cell surface as was found for 
non-dissociating receptor antibody complexes. We are now in 
the process of investigating the intraceUular localisation of 
LRP/~z2MR and Lf after prolonged endocytosis of Lf. 
The extension of our understanding of the physiologic per- 
formance of this receptor brought upon by a new ligand is to 
this end speculative. The demonstration of LRP/~2MR as the 
sole demonstrable protein mediating endocytosis of Lf from 
plasma into liver in the intact organism supported the idea of 
physiological importance. The detection of extremely stable 
Lf-LRP/~2MR complexes in the intrinsic environment, the en- 
dosome, is a strong argument that this reaction occurs in vivo 
and has the potency of regulating receptor levels at the cell 
surface. 
Lf in plasma is derived from leukocytes activated at sites of 
tissue remodelling during the acute inflammatory response. 
This process elevates plasma Lf concentrations tenfold and 
even more at the site of the acute response. Other ligands of 
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LRP/ct2MR like ~2M, PA/PAI- land apoE are also involved in 
these metabolic situations [36-40] pointing towards a concerted 
action of their receptor in this condition. As an iron complexing 
glycoprotein, Lf might sequester free iron in the extracellular 
space delivering it via LRP/c~2MR mediated endocytosis into 
hepatocytes and other cells expressing LRP/~2MR, like macro- 
phages. Our finding that Lf is most avidly bound around pH 
6 implicates that the Lf-LRP/c~zMR interaction provides a pow- 
erful system in a florid inflammatory environment. It is there- 
fore attractive to speculate that Lf is a member of the LRP/ 
ct2MR ligand family that is involved in tissue remodelling at 
sites of inflammation or of physiologic processes. As a common 
feature they are, after having fulfilled a particular function, 
bound and internalised by LRP/~2MR thus signalling the status 
of the extracellular events. 
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